Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort

Blood (2025) 146 (Supplement 1): 662.

https://doi.org/10.1182/blood-2025-662

Published: 2025

Journal Articles

High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort

Blood (2025) 146 (Supplement 1): 5940.

https://doi.org/10.1182/blood-2025-5940

Published: 2025

Journal Articles

Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Marie José Kersten, Kirsten Saevels, Evelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, Claire Vennin, Eva Santermans, Anna D. D. van Muyden, Jeevan Shetty, Esmée P. Hoefsmit, Omotayo Fasan, Maria T. Kuipers, Sébastien Anguille, Joost S.P. Vermaat

Blood (2024) 144 (Supplement 1): 93.

https://doi.org/10.1182/blood-2024-205360

Published: 2024

Journal Articles

Oral Minocycline As Systemic Therapy for Uncomplicated Venous Access Device-Related Bloodstream Infection with Coagulase-Negative Staphylococci in Patients after Allogeneic Hematopoietic Cell Transplantation

Firas Bayoudh, Julie Descy, Corentin Fontaine, Frederic Baron, Evelyne Willems, Yves Beguin, Jean-Baptiste Giot, Sophie Servais

Blood (2021) 138 (Supplement 1): 4859.

https://doi.org/10.1182/blood-2021-146355

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society

Yves Beguin, MD PhD, Pierre Zachee, MD PhD, Johan Maertens, MD PhD, Tessa Kerre, MD PhD, Aurelie Ory, Laurence Seidel, Carlos Graux, MD PhD, Philippe Lewalle, MD PhD, Michel Van Gelder, PhD MD, Koen Theunissen, Evelyne Willems, MD PhD, Marie-Paule Emonds, Ann De Becker, Frederic Baron

Blood (2014) 124 (21): 542.

https://doi.org/10.1182/blood.V124.21.542.542

Published: 2014

Journal Articles

Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Aurélie Jaspers, MD, Frederic Baron, MD PhD, Johan Maertens, MD PhD, Bernard J. M. De Prijck, MD, Henri (Rik) Schots, MDPhD, Christophe Bonnet, MD PhD, Kaoutar Hafraoui, MD, Evelyne Willems, MD PhD, Sophie Servais, MD PhD, Georges Fillet, MD PhD, Yves Beguin, MD PhD

Blood (2014) 124 (21): 3948.

https://doi.org/10.1182/blood.V124.21.3948.3948

Published: 2014

Journal Articles

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Aurélie Jaspers, Frédéric Baron, Évelyne Willems, Laurence Seidel, Kaoutar Hafraoui, Gaetan Vanstraelen, Christophe Bonnet, Yves Beguin

Blood (2014) 124 (1): 33–41.

https://doi.org/10.1182/blood-2014-01-546333

Published: 2014

Includes: Supplemental data

Journal Articles

Day 100 PET Scan Positivity Predicts for Worse Survival in Lymphoma Patients Given Allogeneic Peripheral Blood Stem Cells After Non-Myeloablative Conditioning,

Aurélie Jaspers, Pacome Fosse, Nadia Withofs, Marie Lejeune, Evelyne Willems, Kaoutar Hafraoui, Roland Hustinx, Frederic Baron, MD, PhD, Yves Beguin, MD, PhD

Blood (2011) 118 (21): 4155.

https://doi.org/10.1182/blood.V118.21.4155.4155

Published: 2011

Journal Articles

Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age.

Emilie Castermans, Muriel Hannon, Remi Cheynier, Laurence Seidel, Stéphanie Humblet-Baron, Evelyne Willems, Stephanie Corbier, Andre Gothot, Vincent Geenen, Brenda M. Sandmaier, Rainer F Storb, Yves Beguin, Frederic Baron

Blood (2009) 114 (22): 1149.

https://doi.org/10.1182/blood.V114.22.1149.1149

Published: 2009

Journal Articles

Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 and Acute Graft-Versus-Host Disease After Allogeneic Hematopietic Cell Transplantation with Nonmyeloablative Conditioning.

Stéphanie Humblet-Baron, Evelyne Willems, Olivier Dengis, Laurence Seidel, Yves Beguin, Frederic Baron

Blood (2009) 114 (22): 2269.

https://doi.org/10.1182/blood.V114.22.2269.2269

Published: 2009

Journal Articles

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Yves Beguin, Johan Maertens, Bernard De Prijck, Rik Schots, MD, Pascale Frere, Christophe Bonnet, Kaoutar Hafraoui, Evelyne Willems, Gaetan Vanstraelen, Marie Lejeune, Koen Theunissen, Georges Fillet, Frederic Baron

Blood (2008) 112 (11): 54.

https://doi.org/10.1182/blood.V112.11.54.54

Published: 2008

Journal Articles

Pegfilgrastrim Compared with Filgrastim after Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation.

Gaetan Vanstraelen, MD, Pascale Frère, MD, Marie-Christine Ngirabacu, MS, Evelyne Willems, MD, Georges Fillet, MD, Yves Beguin, MD

Blood (2005) 106 (11): 5287.

https://doi.org/10.1182/blood.V106.11.5287.5287

Published: 2005

Journal Articles

Thrombotic Microangiopathy™ after Allogeneic Peripheral Blood Stem Cell Transplantation with Nonmyeloablative Conditioning (NMSCT) Compared with Myeloablative Conditioning (MSCT).

Evelyne Willems, MD, Frédéric Baron, MD, PhD, Georges Fillet, MD, PhD, Yves Beguin, MD, PhD

Blood (2005) 106 (11): 1774.

https://doi.org/10.1182/blood.V106.11.1774.1774

Published: 2005

Journal Articles

Nonmyeloablative Stem Cell Transplantation with CD8-Depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Trial.

Evelyne Willems, MD, Emilie Castermans, Frédéric Baron, MD, PhD, Etienne Baudoux, MD, Nadine Wanten, Christophe Bonnet, MD, Kaoutar Hafraoui, MD, Pascale Frère, MD, Georges Fillet, MD, PhD, Yves Beguin, MD, PhD

Blood (2005) 106 (11): 1075.

https://doi.org/10.1182/blood.V106.11.1075.1075

Published: 2005

Journal Articles

Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.

Pascale Frère, MD, Frédéric Baron, MD, Christoffe Bonnet, MD, Kaoutar Hafraoui, MD, Maguy Pereira, RN, Evelyne Willems, MD, Georges Fillet, MD, PhD, Yves Beguin, MD, PhD

Blood (2004) 104 (11): 5086.

https://doi.org/10.1182/blood.V104.11.5086.5086

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort

High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort

Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Oral Minocycline As Systemic Therapy for Uncomplicated Venous Access Device-Related Bloodstream Infection with Coagulase-Negative Staphylococci in Patients after Allogeneic Hematopoietic Cell Transplantation

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society

Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Day 100 PET Scan Positivity Predicts for Worse Survival in Lymphoma Patients Given Allogeneic Peripheral Blood Stem Cells After Non-Myeloablative Conditioning,

Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age.

Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 and Acute Graft-Versus-Host Disease After Allogeneic Hematopietic Cell Transplantation with Nonmyeloablative Conditioning.

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Pegfilgrastrim Compared with Filgrastim after Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation.

Thrombotic Microangiopathy™ after Allogeneic Peripheral Blood Stem Cell Transplantation with Nonmyeloablative Conditioning (NMSCT) Compared with Myeloablative Conditioning (MSCT).

Nonmyeloablative Stem Cell Transplantation with CD8-Depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Trial.

Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only